Delivered under local anaesthesia as a day case procedure, ePORE® therapy can be used in combination with chemotherapy for the local control of a wide range of skin cancers.
Addressing critical unmet challenges in global skin and gastrointestinal cancer treatment.
GI cancers account for 26% of the global cancer incidence and 35% of all cancer related deaths in 2018.
M. Arnold, "Global Burden of 5 Major Types of Gastrointestinal Cancer", Gastroenterology, no. https://doi.org/10.1053/j.gastro.2020.02.068, 2020.
By 2040, the global number of new cases of GI cancers are predicted to increase by 58% to 7.5 million.
M. Arnold, “Global Burden of 5 Major Types Of Gastrointestinal Cancer,” Gastroenterology, no. https:// doi.org/10.1053/j.gastro.2020.02.068, 2020
By 2040, global numbers of deaths from GI cancers are predicted to increase by 73% to 5.6 million.
M. Arnold, “Global Burden of 5 Major Types Of Gastrointestinal Cancer,” Gastroenterology, no. https:// doi.org/10.1053/j.gastro.2020.02.068, 2020.
In the UK, operating theater running costs are a median of £16 per minute. ePORE® therapy can be performed as a day case procedure in < 1 hour.
Volpin A, Khan O, Haddad F. Theater Cost Is £16/Minute So What Are You Doing Just Standing There?. J Arthroplasty. 2016;31(1):22-26. doi:10.1016/j.arth.2015.08.008
Targeted Therapy. Big Results.
Improved Patient Experience
Precision-based technology, so only targets tumour tissue, thereby preserving healthy tissue
Minimal side effects
Reduces/stops bleeding associated with GI cancers
Preserves cosmesis and function of treated area
Cost effective
Can be performed under local anaesthetic therefore reducing cost associated with the procedure
Patients are treated as a day-case procedure which reduces time spent in hospital
An alternative treatment option
For those who are at risk of going under general anaesthetic or suffer with comorbidities
Can be used in conjunction with other standard treatments (chemotherapy, surgery)
Repeatable treatment
Years of Experience
We bring together some of the best minds in electroporation and therapeutic development expertise.
Dr. Declan Soden
Founder & Chief Executive Officer
Colin Forde
Chief Operating Officer
Simon Ombler
Sales & Marketing Director
Seán Kinsella
Chief Technical Officer
Patient Experience
Hear about the positive experience of a skin cancer patient who underwent ePORE® therapy treatment.
